NEXTCURE, INC Debt Securities, Available-for-sale, Realized Loss
NEXTCURE, INC (NXTC) reported Debt Securities, Available-for-sale, Realized Loss of $0 for the 3-month period ending 2026-06-30, per its S-4 filed 2026-08-18.
Financial Statements › Income Statement › Other Income
us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss · last filed 2026-08-18
- NEXTCURE, INC debt securities, available-for-sale, realized loss for the quarter ending 2026-06-30 was $0.00.
- NEXTCURE, INC debt securities, available-for-sale, realized loss for the quarter ending 2025-12-31 was $0.00.
- NEXTCURE, INC debt securities, available-for-sale, realized loss for the quarter ending 2025-09-30 was $0.00.
- NEXTCURE, INC debt securities, available-for-sale, realized loss for the quarter ending 2025-06-30 was $0.00.
- NEXTCURE, INC debt securities, available-for-sale, realized loss for fiscal 2023 was $0.00.
| Period end | Debt Securities, Available-for-sale, Realized Loss 3 month | Debt Securities, Available-for-sale, Realized Loss 6 month | Debt Securities, Available-for-sale, Realized Loss 9 month | Debt Securities, Available-for-sale, Realized Loss 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 S-4 · filed 2026-08-18 | |||
| 2025-12-31 | $0.00 derived: S-4 12 month − 10-Q 9 month · filed 2026-08-18 | $0.00 derived: sum of 2 quarters · filed 2026-08-18 | $0.00 derived: sum of 3 quarters · filed 2026-08-18 | $0.00 S-4 · filed 2026-08-18 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-05 | $0.00 derived: sum of 2 quarters · filed 2026-08-18 | $0.00 10-Q · filed 2025-11-05 | $0.00 derived: sum of 4 quarters · filed 2026-08-18 |
| 2025-06-30 | $0.00 S-4 · filed 2026-08-18 | $0.00 S-4 · filed 2026-08-18 | $0.00 derived: sum of 3 quarters · filed 2026-08-18 | $0.00 derived: sum of 4 quarters · filed 2026-08-18 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-07 | $0.00 derived: sum of 2 quarters · filed 2026-08-18 | $0.00 derived: sum of 3 quarters · filed 2026-08-18 | $0.00 derived: sum of 4 quarters · filed 2026-08-18 |
| 2024-12-31 | $0.00 derived: S-4 12 month − 10-Q 9 month · filed 2026-08-18 | $0.00 derived: sum of 2 quarters · filed 2026-08-18 | $0.00 derived: sum of 3 quarters · filed 2026-08-18 | $0.00 S-4 · filed 2026-08-18 |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-05 | $0.00 derived: sum of 2 quarters · filed 2025-11-05 | $0.00 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-07 | $0.00 10-Q · filed 2025-08-07 | ||
| 2023-12-31 | $0.00 10-K · filed 2025-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |